🇺🇸 FDA
Pipeline program

MSC-derived exosomes

KY20230214-V04

Phase 1 mab active

Quick answer

MSC-derived exosomes for Long COVID-19 Syndrome is a Phase 1 program (mab) at Regen BioPharma Inc with 1 ClinicalTrials.gov record(s).

Program details

Company
Regen BioPharma Inc
Indication
Long COVID-19 Syndrome
Phase
Phase 1
Modality
mab
Status
active

Clinical trials